Washington, Feb 22 (ANI): Scientists at Albert Einstein College of Medicine of Yeshiva University have developed an experimental vaccine that appears to protect against an increasingly common and particularly deadly form of pneumococcal pneumonia.
The new vaccine was tested in an animal model.
Pneumococcal pneumonia can occur when the lungs are infected with the bacterial species Streptococcus pneumoniae (also known as pneumococcus).
"Like many microbes that cause pneumonia, pneumococcus is spread from person to person through coughing or sneezing," said principal investigator Liise-anne Pirofski.
Symptoms include cough, fever, shortness of breath, and chest pain.
A pediatric vaccine has dramatically reduced the incidence of pneumococcal disease in children and adults, both by protecting vaccinated children and by reducing person-to-person transmission of the bacterium to others - a phenomenon known as herd immunity.
"The pediatric vaccine is a great victory for modern medicine, but it doesn't cover all strains of disease-causing pneumococcus - some of which have recently emerged and are very virulent," said Pirofski.
The researchers focused on developing a vaccine against serotype 3 - a pneumococcal strain that was not included in the pediatric vaccine used for the past decade and that has emerged as a cause of serious pneumonia in adults and children.
Serotype 3 can trigger inflammation so overwhelming that it can result in very severe disease or even death.
The goal of this study was to produce a vaccine consisting of a live, attenuated (weakened) version of serotype 3 S. pneumoniae.
To create their vaccine, the researchers focused on the serotype 3 gene that codes for pneumolysin, a toxin produced by all pneumococcal strains.
The researchers replaced this gene with a synthetic version that they hoped would reduce the amount of toxin produced.
Altering the pneumolysin gene in the seroptype 3 bacteria resulted in less pneumolysin toxin produced in vitro.
When mice were injected with either attenuated or unattenuated serotype 3 bacteria, mice receiving the attenuated strain developed an inflammatory response much weaker than was observed in mice receiving the unattenuated serotype 3 strain.
Most important, of the five mice injected with the attenuated strain, four survived a subsequent challenge from the highly virulent unattenuated serotype 3 strain, which was lethal in five of five unvaccinated, control mice.
The study was published in the Journal of Infectious Diseases. (ANI)